An exposé during the China Central Television (CCTV) 315 Gala on the evening of March 15th highlighted issues surrounding "universal" exosome products, naming Hunan Lisai Pharmaceutical Co., Ltd. as an involved company.

Corporate information reveals that Hunan Lisai Pharmaceutical Co., Ltd. was established in June 2021, with a legal representative named Xiao Jingyang and a registered capital of 3 million RMB. Its business scope includes medical device technology development and management of healthcare industry projects. According to administrative penalty records, in June 2025, the company was fined and confiscated a total of over 220,000 yuan by the Hunan Provincial Medical Products Administration for violating regulations stipulated in the "Regulations for the Supervision and Administration of Medical Devices."

The company's official website states that Hunan Lisai Pharmaceutical is based in Changsha, Hunan, and operates a center in the Guangzhou Beauty Expo City. It specializes in OEM/ODM for Class II high-end medical devices, offering a range of products that can be supplied directly to hospitals and pharmacies. The company holds approvals from the National Medical Products Administration for products such as anti-HPV gel dressings, medical gynecological gels, recombinant humanized collagen type III liquid dressings, recombinant humanized collagen type III gel dressings, recombinant humanized collagen type III wound dressings, and scar repair dressings.

Attempts to contact Hunan Lisai Pharmaceutical Co., Ltd. via its national service hotline, which is the same as its business registration number, were unsuccessful as the call went unanswered.